A photo of Scott Wexelblatt.

Regional Director of Newborn Services, Perinatal Institute

Associate Professor, UC Department of Pediatrics



Board Certified

My Biography & Research


Working in medicine — particularly pediatrics — has long been my dream. At a young age, I was inspired by my own pediatrician, Dr. Marshall “Buzz” Land, who would later become my mentor at the University of Vermont College of Medicine.

Throughout my career, I’ve noticed a need for standardizing and improving care. This insufficiency drew me to research. I have a particular interest in neonatal opioid withdrawal syndrome.

The overall goals of my work are to reduce length of stay, lower the percentage of infants requiring medications and reduce days of opioid treatment.

I was a faculty member and part of the Neonatal Abstinence Syndrome project with the Ohio Perinatal Quality Collaborative (OPQC), which focuses on reducing preterm births and improving newborn and maternal outcomes.

Clinical Interests

Neonatal Abstinence Syndrome

Academic Affiliation

Associate Professor, UC Department of Pediatrics

Clinical Divisions

Neonatology, Perinatal

Research Divisions


Blog Posts

Awareness Needed

BlogSafety and Prevention

Awareness Needed: Babies Born With Drug Withdrawal

By Dr. Scott Wexelblatt10/9/2013

My Education

MD: University of Vermont College of Medicine, Burlington, VT, 1996.

Residency: Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.

Certification: American Board of Pediatrics, 1999.

My Publications

Physiologic Indirect Response Modeling to Describe Buprenorphine Pharmacodynamics in Newborns Treated for Neonatal Opioid Withdrawal Syndrome. Mizuno, T; McPhail, BT; Kamatkar, S; Wexelblatt, S; Ward, L; Christians, U; Akinbi, HT; Vinks, AA. Clinical Pharmacokinetics. 2021; 60:249-259.

Pharmacotherapy of neonatal opioid withdrawal syndrome: a review of pharmacokinetics and pharmacodynamics. van Hoogdalem, MW; McPhail, BT; Hahn, D; Wexelblatt, SL; Akinbi, HT; Vinks, AA; Mizuno, T. Expert Opinion on Drug Metabolism and Toxicology. 2021; 17:87-103.

Orchestrated Testing of Formula Type to Reduce Length of Stay in Neonatal Abstinence Syndrome. Kaplan, HC; Kuhnell, P; Walsh, MC; Crowley, M; McClead, R; Wexelblatt, S; Ford, S; Provost, LP; Lannon, C; Macaluso, M. Pediatrics. 2020; 146.

Subclinical and Overt Newborn Opioid Exposure: Prevalence and First-Year Healthcare Utilization. Percy, Z; Brokamp, C; McAllister, JM; Ryan, P; Wexelblatt, SL; Hall, ES. Journal of Pediatrics. 2020; 222:52-58.e1.

Medication treatment for opioid use disorder in expectant mothers (MOMs): Design considerations for a pragmatic randomized trial comparing extended-release and daily buprenorphine formulations. Winhusen, T; Lofwall, M; Jones, HE; Wilder, C; Lindblad, R; Schiff, DM; Wexelblatt, S; Merhar, S; Murphy, SM; Greenfield, SF; et al. Controlled Clinical Trials. 2020; 93.

Reported Prevalence of Maternal Hepatitis C Virus Infection in the United States. Rossi, RM; Wolfe, C; Brokamp, R; McAllister, JM; Wexelblatt, S; Warshak, CR; Hall, ES. Obstetrics and Gynecology. 2020; 135:387-395.

Cohort Analysis of a Pharmacokinetic-Modeled Methadone Weaning Optimization for Neonatal Abstinence Syndrome. Hall, ES; Meinzen-Derr, J; Wexelblatt, SL. Journal of Pediatrics. 2020; 167:1221-5.e1.

Addressing the Disease Burden of Vertically Acquired Hepatitis C Virus Infection Among Opioid-Exposed Infants. Protopapas, S; Murrison, LB; Wexelblatt, SL; Blackard, JT; Hall, ES. Open Forum Infectious Diseases. 2019; 6.

Developmental Disorders and Medical Complications Among Infants with Subclinical Intrauterine Opioid Exposures. Hall, ES; McAllister, JM; Wexelblatt, SL. Population Health Management. 2019; 22:19-24.

Surveillance of Intrauterine Opioid Exposures Using Electronic Health Records. Hall, ES; Wexelblatt, SL; Greenberg, JM. Population Health Management. 2018; 21:486-492.